News and Announcements
Imugene Announces New Strategic Partnership with the Baker Institute
- Published February 28, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Imugene Limited (ASX:IMU) incurred expenditure of $2.27m, which was offset in large part by an expected rebate of $0.77m under the Australian Governments R&D tax incentive scheme. The majority of expense, being $1.65m, were incurred on research and development, with the balance being payroll and administration costs.
KEY TAKEAWAYS:
- New strategic partnerships with the Baker Institute investigating the opportunities for small molecules in immune-oncology.
- Four new mimotope patents filed to expand Imugene pipeline into B-cell vaccine compositions and franchise.
- Successful $3.2M private placement with sophisticated and institutional investors.
- Cash and cash equivalents 31 December 2016: Up 41% on pcp to $3.8M.
- Phase 1b/2 trial in patients with metastatic gastric cancer to recruit in 2017.
- Loss for the 6 months to 31 December 2016: Up 45.00% on previous comparable period (‘pcp’) to $1.49M.
Imugene is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
